SRI - Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment

Enochian BioSciences (ENOB) shares skyrocket to more than double their value during the premarket session after the U.S. FDA accepted a Pre-IND ((Investigational New Drug)) request for a potential functional cure or treatment of HIV.The request was based on the results of a 54-year old man living with HIV who had failed to suppress the virus with antiviral therapy.The patient subsequently achieved viral control for 255 days with an innovative treatment of Natural Killer ((NK)) and Gamma Delta T-cells ((GDT)) collected from another person."Pre-IND is an important step to exploring the possibility of testing this novel NK-GDT treatment," Mark Dybul, an expert in HIV and Executive Vice Chairperson of the Board of Enochian BioSciences said."Because the promising early results are only in one person, it is important to study the approach in a larger population," he added.The company's share are up more than 50% YTD.Seeking Alpha contributor Edmund Ingham in a recent

For further details see:

Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment